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Psychopharmacology for the Clinician

The information in this column is not intended as a definitive treatment strategy but as a suggested approach for clinicians treating patients
with similar histories. Individual cases may vary and should be evaluated carefully before treatment is provided. The patient described in this
column is a composite with characteristics of several real patients.
Identification and management of
cryptic bipolarity in patients with TRD
A 32-year-old woman with recurrent
major depressive disorder was referred for
management of treatment-resistant depression (TRD), having failed to respond
to 2 adequate antidepressant trials for the
index episode. The depressive episode was
characterized by symptoms of sad mood,
anhedonia, increased appetite, hypersomnia, poor concentration, psychomotor retardation and fatigue. The symptoms were
severe enough to have caused substantial
functional impairment despite adherence
to prescribed medications. She denied a
prior history of manic or psychotic symptoms. There was no history of obsessions
or compulsions, but she had experienced
occasional panic attacks. The family history was unknown, as she was adopted at
birth. Physically, she was healthy, and recent blood work confirmed normal thyroid
function.
There was a history of poor response to
several trials of antidepressants including
40 mg of fluoxetine (8 wk), 200 mg of sertraline (6 wk) and 225 mg of desipramine
(6 wk). She was currently taking 300 mg of
bupropion, 375 mg of venlafaxine, 750 mg
of lithium, 50 mg of quetiapine and 2 mg
of clonazepam (as needed). For the index
episode, she received 300 mg of bupropion (8 wk) followed by the addition of
225 mg of venlafaxine. Her condition improved somewhat with bupropion, but
she experienced a loss of response after
4 weeks. On titration of the venlafaxine
dose, psychomotor agitation, racing
thoughts, irritability, distractibility, insomnia and suicidal ideation developed, and
lithium and quetiapine were added. She
had similar symptoms with desipramine
for a previous episode. She refused a trial
of electroconvulsive therapy.
The patient was suspected to have TRD

with a bipolar diathesis. Clues to the bipolar nature of depression included a history of atypical symptoms of depression,
emergent manic symptoms following the
use of antidepressants, poor response to
prior antidepressants and a loss of antidepressant response. Venlafaxine, and
then bupropion, were slowly tapered off.
Even though the antidepressants were
withdrawn over several weeks, she experienced symptoms of antidepressant
discontinuation syndrome, including worsening of insomnia and agitation. The quetiapine dose was optimized to 150 mg and
the lithium dose remained unaltered. At
the higher dose of quetiapine, she no
longer needed clonazepam, which was
discontinued. The patient has remained
free of depressive or hypomanic symptoms for about 2 years.
This patient’s case demonstrates the
challenges of managing TRD in contemporary clinical practice. Reasons for poor
response to antidepressant therapy include treatment nonadherence, inadequate dose and duration of antidepressant
treatment, comorbid anxiety or substance
use disorders and concomitant psychotic
symptoms.1,2 A recent study suggests that
about 40% of patients with a history of
major depression had a history of subthreshold mania.3 Bipolarity may be more
prevalent among patients with “unipolar”
TRD.4,5 A diagnostic re-evaluation should
be the first step in the management of
TRD. Attention to the cross-sectional
symptomatology and the longitudinal illness course is important to clarify the
diagnosis. Depressed patients should be
routinely screened for subthreshold manic
symptoms before the initiation of antidepressants. Variability in clinical presentation of depressive mixed states and the
lack of consensus about their diagnostic
criteria makes their detection difficult. Use
of antidepressants in individuals with a

bipolar diathesis may convert the typical
presentation of hypersomnic, retarded depression into an agitated, anxious mood
state with accompanying insomnia and
racing thoughts. Patients taking drugs like
neuroleptics and benzodiazepines that
have a preferential effect against manic
symptoms may no longer experience
hypomania resulting in a clinical state
dominated by depressive symptoms.
Therefore, it is important to be aware of
the illness course before and after the introduction of antidepressants.
Patients with TRD with a clear bipolar
diathesis should be managed with mood
stabilizers.5,6 Antidepressants should be
tapered off slowly with close monitoring
for symptoms of antidepressant discontinuation syndrome. For patients taking
antidepressants and mood stabilizers, discontinuation of antidepressants and continued treatment with mood stabilizers
may be effective in alleviating depression.
Others may require optimized doses of
mood stabilizers. Whereas polypharmacy
may be unavoidable, every effort should
be made to keep the overall number of
medications used to a minimum. In general, the same guidelines used for bipolar
depression should apply to the management of bipolar TRD.7
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